| ONGLYZATM (saxagliptin) US Label Update Provides Further Evidence Regarding ... - Live-PR.com (press release) |
|
|
Live-PR.com (press release) The renal study investigated the safety and efficacy of ONGLYZA in patients with moderate to severe renal impairment or end-stage renal disease (ESRD). The 12-week data showed that ONGLYZA 2.5 mg once daily significantly improved glycoslated hemoglobin |